非酒精性脂肪性肝病的饮食治疗热点

doi:10.3969/j.issn.1672-5069.2017.05.006

Abstract

Li Yan，Wang Caihua.. Hot spots in dietary therapy in patients with non-alcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 529-531.

[1] Africa JA，Newton KP，Schwimmer JB. Lifestyle interventions including nutrition，exercise，and supplements for nonalcoholic fatty liver disease in children. Dig Dis Sci，2016，61（5）:1375-1386.
[2] Younossi ZM，Koenig AB，Abdelatif D，et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence，incidence，andoutcomes.Hepatology，2016，64（1）:73-84.
[3] Fan JG，Farrell GC.Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol，2009，50（1）:204-210.
[4] Chalasani N，Younossi Z，Lavine JE，et al. The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association，American Association for the Study of Liver Diseases，and American College of Gastroenterology. Gastroenterology，2012，142（7）:1592-609.
[5] Rinella ME. Nonalcoholic fatty liver disease:a systematic review. JAMA，2015，313（22）:2263-2273.
[6] Ratziu V，Goodman Z，Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol，2015，62（Suppl 1）:S65-75.
[7] Fan JG，Cao HX. Role of diet and nutritional management in non-alcoholic fatty liver disease. J Gastroenterolo Hepatol，2013，28 （Suppl 4）:81-87.
[8] Huang D，Dhawan T，Young S，et al. Fructose impairs glucose-induced hepatic triglyceride synthesis. Lipids Health Dis，2011，10:20.
[9] Jegatheesan P，De Bandt JP. Fructose and NAFLD:The multifaceted aspects of fructose metabolism. Nutrients，2017，9（3）:[ahead of print].
[10] Abdelmalek MF，Suzuki A，Guy C，et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology，2010，51（6）:1961-1971.
[11] Chung M，Ma J，Patel K，et al. Fructose，high-fructose corn syrup，sucrose，and nonalcoholic fatty liver disease or indexes of liver health:a systematic review and meta-analysis. Am J Clin Nutrit，2014，100（3）:833-849.
[12] Chiu S，Sievenpiper JL，de Souza RJ，et al. Effect of fructose on markers of non-alcoholic fatty liver disease（NAFLD）:a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutrit，2014，68（4）:416-423.
[13] Mosca A，Nobili V，De Vito R，et al. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. J Hepatol，2017，66（5）:1031-1036.
[14] Perreault L，Pan Q，Mather KJ，et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk：results from the Diabetes Prevention Program Outcomes Study. Lancet，2012，379（9833）:2243-2251.
[15] European Association for the Study of the L，European Association for the Study of D，European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol，2016，64（6）:1388-1402.
[16] Sears B. Comparison of the Atkins，zone，ornish，and LEARN diets for change in weight and related risk factors among overweight premenopausal women. Medscape Gen Med，2007，9（3）:57.
[17] Bielohuby M，Sisley S，Sandoval D，et al. Impaired glucose tolerance in rats fed low-carbohydrate，high-fat diets. Am J Physiol Endocrinol Metab，2013，305（9）:E1059-1070.
[18] Mahady SE，George J. Exercise and diet in the management of nonalcoholic fatty liver disease. Metab Clin Experiment，2016，65（8）:1172-1182.
[19] Rinella ME，Sanyal AJ. Management of NAFLD:a stage-based approach. Nat Rev Gastroenterolo Hepatol，2016，13（4）:196-205.
[20] Jump DB，Depner CM，Tripathy S，et al. Potential for dietary omega-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer. Adv Nutrit，2015，6（6）:694-702.
[21] Ng M，Fleming T，Robinson M，et al. Global，regional，and national prevalence of overweight and obesity in children and adults during 1980-2013:a systematic analysis for the Global Burden of Disease Study 2013. Lancet，2014，384（9945）:766-781.
[22] Promrat K，Kleiner DE，Niemeier HM，et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology，2010，51（1）:121-129.
[23] Thoma C，Day CP，Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults:a systematic review. J Hepatol，2012，56（1）:255-266.
[24] Musso G，Cassader M，Rosina F，et al. Impact of current treatments on liver disease，glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease （NAFLD）:a systematic review and meta-analysis of randomised trials. Diabetologia，2012，55（4）:885-904.
[25] Qin J，Li R，Raes J，et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature，2010，464（7285）:59-65.
[26] Kovatcheva-Datchary P，Arora T. Nutrition，the gut microbiome and the metabolic syndrome. Best Prac Res Clin Gastroenterol，2013，27（1）:59-72.
[27] Al-Lahham SH，Roelofsen H，Priebe M，et al. Regulation of adipokine production in human adipose tissue by propionic acid. Eur J Clin Invest，2010，40（5）:401-407.
[28] Vajro P，Mandato C，Licenziati MR，et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediat Gastroenterol Nutrit，2011，52（6）:740-743.
[29] Eslamparast T，Poustchi H，Zamani F，et al. Synbiotic supplementation in nonalcoholic fatty liver disease:a randomized，double-blind，placebo-controlled pilot study. Am J Clin Nutrit，2014，99（3）:535-542.
[30] Birerdinc A，Stepanova M，Pawloski L，et al. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Therapeut，2012，35（1）:76-82.

Hot spots in dietary therapy in patients with non-alcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[2]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[3]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[4]	. [J]. Journal of Practical Hepatology, 2019, 22(5): 624-635.
[5]	Dai Qingyun, Wang Rundong, Jia Weidong. Prediction of early tumor recurrence by predictive nutritional index in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 561-564.
[6]	Gao Zhiliang, Zhu Xiang. How to achieve the clinical cure of hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 305-308.
[7]	Wang Xiaoxiao, Chen Xinyue. Therapeutic strategy for serum HBsAg clearance in suitable population of chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 309-312.
[8]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[9]	Wang Haifang, Yang Dawei, Jia Bei. Impact of nutrition support and medusa administration on liver function, erythrocyte and platelet parameters in patients with alcoholic liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 381-384.
[10]	Liu Liwei, Zhao Xinyan. Clinicopathological features of drug-induced liver injury [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 160-163.
[11]	Guideline for diagnosis, treatment of liver failure. [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 164-171.
[12]	Zhao Xiaofei, Lin Dongdong, Li Ning, Zang Yunjin, Guo Qingliang, Wu Juanshan. Application of warfarin in dealing with portal vein thrombosis in patients with liver cirrhosis after splenectomy and devascularization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 240-243.
[13]	Wang Zhaoxia, Guan Ke, Fu Sanxian, Wang Huijie. Early administration of enteral nutrition in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 272-275.
[14]	Yusup Tursun, Zhao Yanxia.. Establishment of low-dose diethylnitrosamine-induced liver fibrosis model in rats [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 33-36.
[15]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.